
    
      A total of 85 patients between 16 and 30 years old with ALL of standard risk will be included
      in the study. The aim of this study is to determine the efficacy and safety of the
      administration of DepoCyte® as the only IT prophylaxis of the neuromeningeal relapse in
      patients between 16 and 30 years old diagnosed with ALL of standard risk.

      The study is divided in:

      Screening: 2 weeks before treatment Treatment: 2 years of systemic treatment according to
      PETHEMA LAL-RI-08 Protocol (Induction, Consolidation 1 and 2, Maintenance-1 with reinductions
      and maintenance 2 with no reinductions). Patients will receive DepoCyte® in Induction,
      Consolidation 1 and 2 and Maintenance 1 (first year). Patients will not receive DepoCyte® in
      Maintenance-2 (second year).

      Follow-up: Patients in the study will be followed up for one year
    
  